Source: http://www.bcgsc.ca/faculty/msadar
Timestamp: 2019-04-24 12:30:59+00:00

Document:
Dr. Sadar’s research accomplishments and experience over 22 years is essentially entirely focused on the development of therapeutics for prostate cancer. In 1999, Dr. Sadar discovered a novel drug target for prostate cancer. She then partnered with a chemist, Dr. Andersen, to screen drugs against this target, and discovered a clinical candidate of this drug. Dr. Sadar Founded a biotech company in 2009, called ESSA Pharma Inc, to develop the drug for testing in clinical trials. This was successful and First-in-human clinical trials are currently active at 4 sites in USA and 1 site in Canada Clinical/Trials.gov Identifier: NCT02606123. Only one in a thousand drugs that show promise in laboratory studies and animal models ever reaches human testing. Dr. Sadar’s drug is the first drug in clinical trials that binds to an intrinsically disordered protein region and a first in class drug to the N-terminus of the androgen receptor. The work is precedent in the entire field of steroid hormone receptors, with no other small molecule inhibitor reported to bind to the N-terminus of any other steroid hormone receptor (Andersen et al Cancer Cell 2010; Myung et al JCI 2013). Validation of the novelty of her drug was provided by the USAN council and her drug was given a new stem class “-aniten” and the generic name “ralaniten”. In 2016, Dr. Sadar developed the first imaging agent to detect androgen receptor and its active splice variants in prostate cancer (Imamura et al JCI Insight. 2016). Dr. Sadar has served in numerous leadership roles internationally and is the Y2017 Chair of the USA Army’s Department of Defence’s Programmatic Panel for their Prostate Cancer Research Program. She is the first Canadian to serve in this position. She was the President of the Society of Basic Urologic Research (USA) and a board member of education, research, and scientific advisory committees and boards for American and Canadian non-profit societies. Of note is that Dr. Sadar was recently appointed to the Board of Trustees for Canada’s National Museum of Science and Technology by the Minister of Heritage. Dr. Sadar has served on over 50 grant panels including 5 years on the NIH study session for Drug Discovery & Molecular Pharmacology. Her research has gained considerable media attention over the years with many interviews on radio, newspapers, television, and on the internet. Her research has also received awards such as the USA SWIU/SBUR Award for Excellence in Urologic Research, Simon Fraser University’s Outstanding Alumni Award for Academic Achievements, and the Terry Fox Young Investigator Award. Dr. Sadar has trained 40 students and 18 fellows of which many have gone onto successful medical or scientific careers.
Obst JK and Sadar MD. Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation. Translational Cancer Research. 2016 Jul 22. doi: 10.21037/tcr.2016.07.35.
Marianne Sadar's Complete Publication List with links to selected papers.
Sadar MD and Imamura Y. Wee1 and EPI combo. Filing date: May 9, 2017. ESSA-026/00US.
Sadar MD, Mawji NR, OBst JK, Andersen RJ, Williams DE, Kunzhoung J. Compounds and methods for treating drug-resistant androgen receptor mediated cancers. U.S. Application No. 62/385648. Filing date: September 9, 2016. ESSA-022/00US.
Sadar MD and Leung JK. Compound combinations and methods for treating androgen receptor mediated cancers. Filing date: February 28, 2017. ESSA-025/00US.
Sadar MD and Mawji NR. Androgen receptor activators. Filing date: September 20, 2016.
Andersen RJ, Jian K, Mawji NR, Banuelos CA, Wang J, Yang YC, Sadar MD. Bisphenol derivatives and their use as androgen receptor activity modulators. U.S. Provisional Patent Application No. 62/323196. Filing date: April 15, 2016.
Sadar MD, Kato M, Mawji NR, Wang J. Co-targeting mTOR and the androgen receptor N-terminal domain for prostate cancer. U.S. Provisional Patent Application No. 62/213506. Filing date: September 2, 2015.
Sadar MD, Mawji NR, Banuelos CA, Andersen RJ, Kunzhong J, Bisphenol Ether Derivatives and methods for using the same. U.S. Provisional Patent Application No. 62/131969. Filing date: March 12, 2015.
Andersen RJ, Fernandez JG, Jian K, Sadar MD, Mawji NR, Banuelos CA. Heterocyclic Compounds for Cancer Imaging and Treatment and Metehods for Their Use. U.S. Provisional Patent Application No. 62/102719. Filing date: January 13, 2015.
Sadar MD, Leung J. Compositions and methods for treatment of prostate cancer. U.S. Provisional Appliccation No. 62/130696. Filing date: March 10, 2015.
Andersen RJ, Fernandez JG, Jian K, Sadar MD, Mawji NR, Banuelos CA. Heterocyclic Compounds for Cancer Imaging and Treatment and Methods for Their Use. U.S. Provisional Patent Application No. 62/102719. Filing date: January 13, 2015.
Sadar MD, Mawji NR, Wang J, Imamura Y, Tien A, Andersen RJ, Fernandez JG, Garcia J, Kunzhong J. Halogenated Compounds for Cancer Imaging and Treatment and Methods for Their Use. U.S. Application No. 14/481727. Filing date: September 9, 2014.
Yan L, Andersen RJ, Sadar MD, Mawji NR, Banuelos CA. Androgen Receptor Modulators and Methods for Their Use. U.S. Application No. 62/005714. [PCT/US15/33385] Filing date: May 30, 2014.
Andersen RJ, Fernandez JG, Sadar MD, Banuelos CA, Mawji N, Wang J. Fluoro-Cchloro Bisphenol Ether Compounds and Methods for Their Use. U.S. Provisional Patent Application No. 61/890670. Filing date: October 14, 2013.
Sadar MD, Andersen RJ, Fernandez JG, Yapp DT, Lin KS, Benard F, Tien A. 18F Compounds for Cancer Imaging and Method for Their Use. U.S. Provisional Patent Application No. 61/890679. [PCT/US2012/051923] Filing date: August 22, 2012.
Andersen RJ, Fernandez JG, Garcia J, Kunzhong J, Sadar MD, Mawji NR, Banuelos CA, Wang J, Imamura Y. I Compounds for Cancer Imaging and Methods for Their Use. U.S. Provisional Application No. 61/875556. Filing date: September 9, 2013.
Sadar MD, Mawji NR, Banuelos CA, Andersen RJ, Williams DE. Axamide-3 and Related compounds for Treatment of Cancer. Provisional Patent Application No. U.S. 61/868365. Filing date: August 21, 2013. U.S. Provisional Patent Application No. 61/693693. Filing date: August 27, 2012.
Andersen RJ, Fernandez JG, Sadar MD. Bisphenol Ether Compounds with Novel Bridging Groups and Methods for Their Use. U.S. Provisional Patent Application No. 61/868365. Filing date: July 3, 2013.
Andersen RJ, Sadar MD, Fernandez JG, Mawji NR, Wang J, Banuelos CA. Ester Derivatives of Androgen Receptor Modulators and Methods for Their Use. U.S. Application No. 14/274528. Filing date: May 9, 2014.
Andersen RJ, Sadar MD. Aziridine Bisphenol Ethers and Related compounds and Methods for Their Use. U.S. Application No. 13/863849. Filing date: April 16, 2013.
Andersen RJ, Fernandez JG, Sadar MD, Mawji NR, Banuelos CA, Wang J. Fluorinated Bisphenol Ether Compounds and Methods for Their Use. U.S. Application No. 13/588922. [PCT/US2012/051481] Filing date: August 17, 2012.
Andersen RJ, Fernandez JG, Sadar MD, Mawji NR, Banuelos CA, Wang J. Dibenzylphenyl Compounds and Methods for Their Use. PCT/US2012/033957. Filing date: April 17, 2012.
Andersen RJ, Fernandez JG, Sadar MD, Mawji NR, Banuelos CA, Wang J. Fluorene-9-Bisphenol Compounds and Methods for Their Use. PCT/US2012/033959. Filing date: April 17, 2012.
Andersen RJ, Fernandez JG, Sadar MD, Mawji NR, Banuelos CA, Wang J. Bisphenol Compounds and Methods for Their Use. U.S. Application No. 14/110615. [PCT/US2012/032584] Filing date: April 6, 2012.
Jones S, An J, Sadar MD, Mawji NR, Zoubeidi A. Compositions and methods for treatment of prostate cancer. Filing date: September 7, 2012.
Sadar MD, Mawji NR, Banuelos CA, Andersen RJ, Fernandez JG. Bisphenol Derivatives and Their Use as Androgen Receptor Activity Modulators. U.S. Application No. 13/520729. [PCT/CA2011/000019] Filing date: January 6, 2011.
Sadar MD, Mawji NR, Banuelos CA, Andersen RJ, Fernandez JG. Bisphenol Derivative Therapeuticsc and Methods for Their Use. U.S. Application No. 13/520731. [PCT/CA2011/000021] Filing date: January 6, 2011.
Sadar MD, Combination therapy uses for certain androgen receptor blocking compounds. U.S. Provisional patent application Filed at the USPTO in September, 2010.
Sadar MD, Mawji NR, Banuelos CA, Andersen RJ, Garcia Fernandez J. Achiral Group Containing Bisphenol Derivative Therapeutics and Methods for their Use. Full PCT Application No. P110100034. Filing date: January 6, 2010.
Lam S, Yee J, Kuzyk M, Sin D, Sadar MD, Tammemagi CM. Methods for detecting lung cancer and monitoring treatment response. U.S. Application No. US12/743042. [PCT/CA2008/002070]. Filing date: November 24, 2008.
Sadar MD, Mawji NR, Wang J, Andersen RJ, Williams DR, LeBlanc M. Diglycidic Ether Derivative Therapeutics and Methods for Their Use. U.S. Application No. 12/999037. [PCT/CA2009/000902] Filing date: April 19, 2013.
Sadar MD, Mawji NR, Wang J, Andersen RJ, Williams DE, LeBlanc M, Yan LP. Small Molecular Inhibitors of N-Terminus Activation of the Androgen Receptor. U.S. Application No. 12/999035. [PCT/CA2009/001173] Filing date: August 24, 2009.
Sadar MD, Quayle SN, Hare H. Biomarkers and Methods for the Prognosis of Androgen-Independent Prostate Cancer. U.S. Provisional patent application Filed at the USPTO in March 2009.
Sadar MD, Bruchovsky N, Gout PW, Snoek R, Mawji NR. Peptide inhibitors of androgen-independent activation of androgen receptor. PCT/CA1999/000604. Filing date: June 30, 1999.
U.S. Army Department of Defense Annual Report 2008. Spotlight on Dr.Sadar's research (page 20).

References: Application No. 62
 Application No. 62
 Application No. 62
 Application No. 62
 Application No. 62
 Application No. 62
 Application No. 14
 Application No. 62
 Application No. 61
 Application No. 61
 Application No. 61
 Application No. 61
 Application No. 61
 Application No. 14
 Application No. 13
 Application No. 13
 Application No. 14
 Application No. 13
 Application No. 13
 Application No. 12
 Application No. 12